Sort   by:  
 Page size 
UnknownThe Value of Case Reports in Systematic Reviews from Rare Diseases. The Example of Enzyme Replacement Therapy (ERT) in Patients with Mucopolysaccharidosis Type II (MPS-II).
Not available
S-EPMC7558586 | biostudies-literature
UnknownThe Impact of Excluding Nonrandomized Studies From Systematic Reviews in Rare Diseases: "The Example of Meta-Analyses Evaluating the Efficacy and Safety of Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis".
Not available
S-EPMC8257960 | biostudies-literature
UnknownAgreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases.
Not available
S-EPMC6805333 | biostudies-literature
UnknownInclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design.
Not available
S-EPMC7733004 | biostudies-literature
UnknownExtended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.
Not available
S-EPMC12212146 | biostudies-literature
UnknownNeoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study.
Not available
S-EPMC11472226 | biostudies-literature
Sort   by:  
 Page size